Tag

COVID19 clinical trial

Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published

  MOORESTOWN, NJ, (August 12, 2020) – Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces TRHC’s Precision Pharmacotherapy Research and Development Institute (PPRDI) published the research article, “Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy”, in the August 10, 2020, online edition of the Journal of Clinical Medicine. The article is... Read More

Regence and TRHC Partner on COVID-19 Virtual Clinical Trial to Assess Proposed Treatment Risks

Moorestown, NJ, June 9, 2020 – Regence and Tabula Rasa HealthCare® (NASDAQ: TRHC) announced today that the companies have partnered on a virtual clinical trial to assess the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19. The trial examines de-identified medical information for approximately 500,000 Regence health plan members across multiple lines of business. Regence is a family of health plans in Oregon, Idaho, Utah and select counties... Read More

TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments

Moorestown, NJ, April 29, 2020 – Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announced today it is running a clinical study assessing the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19 in older adults on multiple medications. “This study showcases the depth and breadth of our clinical research capabilities,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “The... Read More